|
Demographic, clinical, and immunological data in association with the ARV treatment regimens |
||||
| Parameters |
ARV treatment regimens |
|||
|
|
||||
| NRTI+NNRTI+PI (n = 15) |
NRTI+NNRTI (n = 6) |
NRTI + PI (n = 13) |
NRTIs (n = 7) |
|
|
|
||||
| Age of study entry (Mean+/-SD, yrs) |
11.9+/-4.3 |
10.8+/-3.4 |
8.8+/-5.1 |
10.4+/-3.0 |
| Length of treatment (Mean+/-SD, yrs) |
7.8+/-3.1 |
6.7+/-2.3 |
5.1+/-2.8 |
5.8+/-2.7 |
| Number of Medications |
||||
| NRTI |
3.7+/-0.7 |
3.3+/-1.0 |
3.1+/-1.0 |
2.7+/-1.1 |
| NNRTI |
1.1 +/-0.2 |
1.2+/-0.4 |
- |
- |
| PI |
1.1+/-0.6 |
- |
1.2+/-0.4 |
- |
| Clinical categories * |
||||
| B |
8 (53.3%) |
3/5 (60.0%) |
4 (30.8%) |
3 (42.9%) |
| C |
7 (46.7%) |
2/5 (40.0%) |
9(69.2%) |
4 (57.1%) |
| Immune categories ** |
||||
| 1 (no suppression) |
10 (66.3%) |
4 (66.7%) |
7 (53.9%) |
3 (42.9%) |
| 2–3 (moderate/severe) |
7 (33.3%) |
2 (33.3%) |
6 (46.1%) |
4 (57.1%) |
| PVL (n, %) |
||||
| <10,000 |
5 (33.3%) |
4 (66.7%) |
2 (15.4%) |
4 (57.1%) |
| ≥ 10,000 |
10 (66.7%) |
2 (33.3%) |
11 (84.6%) |
3 (42.9%) |
| Number of mutations (Mean+/-SD) |
5.7+/-3.8 |
3.5+/-1.6 |
4.7+/-3.2 |
3.7+/-2.3 |
|
*B-moderately, C-severely symptomatic 22,23 ** Immune categories based on age-specific CD4+ T-lymphocyte count.22,23 | ||||
Malhotra et al. AIDS Research and Therapy 2007 4:15 doi:10.1186/1742-6405-4-15 |
||||